# Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

> **NCT04332341** · EARLY_PHASE1 · RECRUITING · sponsor: **Case Comprehensive Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Cell Transplantation

## Interventions

- **DRUG:** Nicotinamide riboside (NR)

## Key facts

- **NCT ID:** NCT04332341
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-19
- **Primary completion:** 2026-07
- **Final completion:** 2026-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04332341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04332341, "Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04332341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*